Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:11:48.548Z.
Calculation as of: 2026-10-06T20:11:48.548Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8ce36116f6c4cf8d6fa5d70ec9ce1d9cbc86489a03ebd5e18b87b9f8ced35068
PE RATIO
N/A
Market Cap
$1.48B
PE Ratio
15.00
TTM Avg
21.09
3Y Avg
55.49
5Y Avg
39.46
Market Cap
$1.49B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.50B
PE Ratio
142.41
TTM Avg
152.77
3Y Avg
83.75
5Y Avg
83.75
Market Cap
$1.45B
PE Ratio
12.36
TTM Avg
30.95
3Y Avg
30.73
5Y Avg
31.04
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.48B | N/A | N/A | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 15.00 | 21.09 | 55.49 | 39.46 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 142.41 | 152.77 | 83.75 | 83.75 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 12.36 | 30.95 | 30.73 | 31.04 |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 8.64 | 9.48 | 9.58 | 16.69 |
| Certara, Inc. (CERT)vs › | $1.44B | N/A | 174.30 | 183.89 | 183.89 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 8.92 | 9.41 | 9.41 | 62.32 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$21.52
Forward EPS (Est.)
$-1.19
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
